Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £435 | £212 | £420 | £1,027 |
| - Cash | £61 | £104 | £141 | £109 |
| + Debt | £109 | £111 | £114 | £9 |
| Enterprise Value | £483 | £220 | £393 | £927 |
| Revenue | £129 | £90 | £140 | £143 |
| % Growth | 43.8% | -36% | -2% | – |
| Gross Profit | £53 | £40 | £69 | £83 |
| % Margin | 41.2% | 44.4% | 49.4% | 57.9% |
| EBITDA | -£14 | -£149 | -£11 | £33 |
| % Margin | -11.1% | -166% | -7.7% | 23.3% |
| Net Income | -£43 | -£157 | -£39 | £19 |
| % Margin | -33.5% | -175.9% | -28% | 13.3% |
| EPS Diluted | -0.42 | -1.63 | -0.41 | 0.22 |
| % Growth | 74.2% | -297.6% | -286.4% | – |
| Operating Cash Flow | -£51 | -£29 | -£13 | £25 |
| Capital Expenditures | -£7 | -£10 | -£16 | -£9 |
| Free Cash Flow | -£58 | -£38 | -£29 | £16 |